Cranoluten
CognitiveKhavinson bioregulator / researchExperimental
Short peptide sold as a CNS/brain bioregulator. Not FDA-approved; evidence is limited to older bioregulator literature.
For research use only.
Key Facts
- CAS
- 169772-06-9
- Molecular Weight (MW)
- 393.39 g/mol
- Half-life
- Not established
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- CNS (proposed)
Overview
Short peptide sold as a CNS/brain bioregulator. Not FDA-approved; evidence is limited to older bioregulator literature.
Protocol
- Dosage Range
- Not established for human use
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Claimed to normalize brain-specific protein synthesis. Mechanism is not established in modern controlled trials.
Targets
CNS (proposed)
Studies
- Khavinson bioregulators— Journal/year not available
Benefits
Historical nootropic-bioregulator category
Potential Side Effects
- Not well characterized
References
- PMID 15587334External link · Year —